Therini Bio highlights data from trial of THN391 for neurodegenerative conditions

Therini Bio has reported positive outcomes from its Phase Ia trial of THN391, a potential treatment for neurodegenerative conditions. The placebo-controlled, double-blind trial evaluated the safety, pharmacokinetics, and tolerability of single and multiple ascending doses of the therapy in healthy volunteers. Results showed that THN391 was well-tolerated with no serious adverse events, a clean hematological profile, and no anti-drug antibody response.

The therapy demonstrated dose-proportional pharmacokinetics, indicating potential for monthly dosing. THN391 is a humanized monoclonal antibody designed to selectively inhibit fibrin-mediated neuroinflammation without affecting coagulation pathways. This approach targets neuronal damage and inflammation caused by fibrin accumulation at vascular dysfunction sites in the retina and brain.

THN391, Therini Bio’s lead candidate, will now undergo two Phase Ib trials targeting Alzheimer's disease and diabetic macular oedema. The results mark a milestone for a new class of immunotherapies targeting neuroinflammation.

03-05-2025